Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TACR1 | P25103 | 1/20 | 0.42 |
| ▸ | TACR3 | P29371 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4966883 | 0.95 | ALDH1A1 (0.41) | ALDH1A1TACR1TACR3MEN1KMT2A | |
| SCHEMBL1447732 | 0.87 | CYP2D6 (0.44) | ALDH1A1MEN1KMT2ACYP2D6CYP2C9 | |
| SCHEMBL26928457 | 0.84 | CYP19A1 (0.44) | ALDH1A1CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL21612946 | 0.84 | MAOB (0.41) | ALDH1A1MEN1KMT2ASMN1; SMN2HPGD | |
| SCHEMBL4036434 | 0.82 | KMT2A (0.46) | ALDH1A1MEN1KMT2ASLC1A3SLC1A2 | |
| SCHEMBL4299022 | 0.82 | YAP1 (0.48) | TACR1MEN1KMT2ATSHR | |
| SCHEMBL27627779 | 0.81 | DDB1 (0.38) | ALDH1A1MEN1KMT2ASLC1A3SLC1A2 | |
| SCHEMBL4038161 | 0.79 | KMT2A (0.47) | ALDH1A1MEN1KMT2ASLC1A3SLC1A2 | |
| SCHEMBL23066959 | 0.79 | TSHR (0.49) | ALDH1A1TACR1TACR3ADAM17NPC1 | |
| SCHEMBL7157038 | 0.79 | CHRM2 (0.46) | ALDH1A1MEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545662-B2 | MK2 inhibitors and uses thereof | XINTHERA, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-12527763-B2 | Pyrrole amide compound and use thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2026-01-20 | — | — | US | disclosed |
| EP-4539840-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | Neuron23, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| US-20250011335-A1 | SUBSTITUTED PYRIDINES, PYRIDAZINES, PYRIMIDINES, AND 1,2,4-TRIAZINES AS TYK2 INHIBITORS | SUDO BIOSCIENCES LIMITED (GB) | 2025-01-09 | — | — | US | disclosed |
| CN-119176794-A | Heterocyclic compound, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2024-12-24 | — | — | CN | disclosed |
| US-12122785-B2 | Substituted pyridines, pyridazines, pyrimidines, and 1,2,4-triazines as TYK2 inhibitors | SUDO BIOSCIENCES LIMITED (GB) | 2024-10-22 | — | — | US | disclosed |
| WO-2023244788-A9 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. (US) | 2024-09-12 | — | — | WO | disclosed |
| US-11987574-B2 | MK2 inhibitors and uses thereof | XINTHERA, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| US-20240124440-A1 | TYK2 INHIBITORS AND USES THEREOF | SUDO BIOSCIENCES LIMITED (GB) | 2024-04-18 | — | — | US | disclosed |
| EP-4313970-A1 | MK2 INHIBITORS AND USES THEREOF | Xinthera, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| EP-1887003-A1 | 3-[4-HETEROCYCLYL -1,2,3-TRIAZOL-1-YL]-N-ARYL-BENZAMIDES AS INHIBITORS OF THE CYTOKINES PRODUCTION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES | Boehringer Ingelheim Pharmaceuticals, Inc. (US) | 2008-02-13 | — | — | EP | disclosed |
| EP-1773780-A4 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2008-01-09 | — | — | EP | disclosed |
| US-20070142371-A1 | Anti-Cytokine Heterocyclic Compounds | COGAN DEREK | 2007-06-21 | — | — | US | disclosed |
| US-7214802-B2 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-05-08 | — | — | US | disclosed |
| EP-1773780-A2 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2007-04-18 | — | — | EP | disclosed |
| EP-1725544-A1 | 3-[4-HETEROCYCLYL-1,2,3-TRIAZOL-1-YL]-N-ARYL-BENZAMIDES AS INHIBITORS OF THE CYTOKINES PRODUCTION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-11-29 | — | — | EP | disclosed |
| US-20060079519-A1 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-04-13 | — | — | US | disclosed |
| WO-2006012227-A2 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2006-02-02 | — | — | WO | disclosed |
| US-20050288338-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2005-12-29 | — | — | US | disclosed |
| WO-2005090333-A1 | 3-‘4-HETEROCYCLYL -1,2,3,-TRIAZOL-1-YL!-N-ARYL-BENZAMIDES AS INHIBITORS OF THE CYTOKINES PRODUCTION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11987574-B2 | MK2 inhibitors and uses thereof | MKNK2, ENPP2, MAPKAPK2 | ALDH1A1 4145/4885TACR1 4809/4885TACR3 4100/4885 |
| US-12122785-B2 | Substituted pyridines, pyridazines, pyrimidines, and 1,2,4-triazines as TYK2 inhibitors | TYK2, JAK1, PDXK | ALDH1A1 3718/4885TACR1 4838/4885TACR3 4729/4885 |
| US-20240124440-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | ALDH1A1 4745/4885TACR1 4883/4885TACR3 4784/4885 |
| US-20250011335-A1 | SUBSTITUTED PYRIDINES, PYRIDAZINES, PYRIMIDINES, AND 1,2,4-TRIAZINES AS TYK2 INHIBITORS | TYK2, PDXK, JAK1 | ALDH1A1 4255/4885TACR1 4855/4885TACR3 4692/4885 |
| US-12527763-B2 | Pyrrole amide compound and use thereof | NR3C2, AVPR2, MC2R | ALDH1A1 2126/4885TACR1 88/4885TACR3 933/4885 |
| US-20070142371-A1 | Anti-Cytokine Heterocyclic Compounds | TNF, IL6, IL1A | ALDH1A1 278/4885TACR1 353/4885TACR3 2989/4885 |
| US-20050288338-A1 | Amido compounds and their use as pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | ALDH1A1 345/4885TACR1 240/4885TACR3 950/4885 |
| US-20060079519-A1 | Anti-cytokine heterocyclic compounds | TNF, IL6, IL1A | ALDH1A1 278/4885TACR1 353/4885TACR3 2989/4885 |
| US-12545662-B2 | MK2 inhibitors and uses thereof | NR3C2, NR2C2, AGTR2 | ALDH1A1 3116/4885TACR1 944/4885TACR3 1733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.